The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.
Batocchi, A. P., Rotondi, M., Caggiula, M., Frisullo, G., Odoardi, F., Nociti, V., Carella,, Tonali, P. A., Mirabella, M., Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta, <<JOURNAL OF NEUROIMMUNOLOGY>>, 2003; 139 (1-2): 150-154. [doi:10.1016/S0165-5728(03)00154-1] [http://hdl.handle.net/10807/20072]
Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta
Batocchi, Anna Paola;Frisullo, Giovanni;Nociti, Viviana;Mirabella, Massimiliano
2003
Abstract
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
